IV-IVC considerations in the development of immediate-release oral dosage form

Journal of Pharmaceutical Sciences

Volumn 94, Issue 7, 2005, Pages 1396-1417

  Li, Shoufeng ^a   He, Handan ^a   Parthiban, Lakshman J ^a   Yin, Hequn ^a   Serajuddin, Abu T M ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Animal models; Bioavailability; Dissolution; Formulation; In silico modeling; In vitro in vivo correlation; In vitro models; Oral absorption; Particle size; Permeability; Solubility

Indexed keywords

2 NAPHTHOIC ACID; ACETIC ACID; BENZOIC ACID; BILE ACID; CALCIUM; CHLORAMPHENICOL; CHLORIDE; DRUG; GLYCOPROTEIN P; HALOPERIDOL; INDOMETACIN; NAFTIDROFURYL; PHENYTOIN; PHOSPHATIDYLCHOLINE; POTASSIUM; POTASSIUM CHLORIDE; POTASSIUM DIHYDROGEN PHOSPHATE; PROTEIN; SODIUM; SODIUM HYDROXIDE; TAUROCHOLIC ACID; TETRACYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS SOLUTION; CELL STRAIN CACO 2; CELL STRAIN HT29; COMPUTER MODEL; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG DOSAGE FORM; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; FIRST PASS EFFECT; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMEDIATE DRUG RELEASE; IN VITRO STUDY; IN VIVO STUDY; INTESTINE FLUID; INTESTINE TRANSIT TIME; IONIC STRENGTH; IONIZATION; MEAN RESIDENCE TIME; MICHAELIS CONSTANT; MONKEY; NONHUMAN; NORMAL HUMAN; OSMOLALITY; PARTICLE SIZE; PARTITION COEFFICIENT; PKA; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT; REVIEW; STOMACH JUICE; STOMACH PH; SURFACE PROPERTY; X RAY DIFFRACTION;

EID: 23844499379     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20378     Document Type: Review

References (119)

1. Charman WN, Porter CJH, Mithani S, Dressman JB. 1997. Physicochemical and physiological mechanisms for the effects of food on drug absorption: The role of lipids and pH. J Pharm Sci 86: 269-282.
2. Horter D, Dressman JB. 1997. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev 25:3-14.
3. Yu LX, Lipka E, Crison JR, Amidon GL. 1996. Transport approaches to the biopharmaceutical design of oral drug delivery systems: Prediction of intestinal absorption. Adv Drug Deliv Rev 19: 359-376.
4. Edwards LJ. 1951. The dissolution and diffusion of aspirin in aqueous media. Trans Faraday Soc 47:1191-1210.
5. Nelson E. 1957. Solution rate of theophylline salts and effects from oral administration. J Am Pharm Assoc Sci Ed 46:608-614.
6. Nelson E. 1958. Comparative dissolution rates of weak acids and their sodium salts. J Am Pharm Assoc Sci Ed 47:297-299.
7. Dakkuri A, Shah AC. 1982. Correlation of in vitro rate of dissolution with in vivo bioavailability: An overview. Pharm Tech, September 67-91.
8. Abdou HM. 1989. Correlation of in vitro rate of dissolution with in vivo bioavailability. Dissolution, bioavailability and bioequivalence, Easton, PA: Mack.
9. Serajuddin ATM. 2002. Poorly aqueous soluble drugs and surface-active solid dispersion carriers. Formulink, Gattefosse Newsletter, No. 7.
10. Amidon GL, Lennernas H, Shah VP, Crison JR. 1995. Theoretical basis for a biopharmaceutical drug classification: Correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
11. FDA. 1997. Guidance for Industry: Dissolution testing of immediate release solid oral dosage forms. August.
12. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta M, Conner DP, Shah VP, Lesko LJ, Chen ML, Lee VHL, Hussain AS. 2002. Biopharmaceutics classification system: The scientific basis for biowaiver extension. Pharm Res 19:921-925.
13. Shore PA, Brodie BB, Hogben CAM. 1957. The Gastric secretion of drugs: A pH partition hypothesis. J Pharmacol Exp Therap 119:361-369.
14. Dressman JB, Amidon GL, Fleisher D. 1985. Absorption potential: Estimating the fraction absorbed for orally administered compounds. J Pharm Sci 74:588-589.
15. Amidon GL, Sinko PJ, Fleisher D. 1988. Estimating human oral fraction dose absorbed: A correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm Res 5:651-654.
16. Sinko PJ, Leesman GD, Amidon GL. 1991. Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharm Res 8:979-988.
17. Goodacre BC, Murry RJ. 1981. A mathematical model of drug absorption. J Clin Hosp Pharm 6: 117-133.
18. Dressman JB, Fleisher D. 1986. Mixing tank model for predicting dissolution rate control of oral absorption. J Pharm Sci 75:109-116.
19. Yu LX, Crison Jr, Amidon GL. 1996. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int J Pharm 140:111-118.
20. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3-25.
21. Johnson KC, Swindell AC. 1996. Guidance in the setting of drug particle size specification to minimize variability in absorption. Pharm Res 13:1795-1798.
22. Galia E, Nicolaides E, Horter D, Lobenberg R, Reppas C, Dressman JB. 1998. Evaluation of various dissolution media for predicting in vivo performance of class I and class II drugs. Pharm Res 15:698-705.
23. Nicolaides E, Galia E, Efthymiopoulos C, Dressman JB, Reppas C. 1999. Forecasting the in vivo performance of four low solubility drugs from their in vivo dissolution data. Pharm Res 16:1876-1882.
24. Pedersen BL, Brondsted H, Lennernas H, Christensen N, Mullertz A, Kristensen HG. 2000. Dissolution of hydrocortisone in human and simulated intestinal fluids. Pharm Res 17:183-189.
25. Dressman JB, Reppas C. 2000. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci 11:S73-S80.
26. Pedersen BL, Mullertz A, Brondsted H, Kristensen HG. 2000. A comparison of the solubility of danazol in human and simulated gastrointestinal fluids. Pharm Res 17:891-895.
27. Kramer SF, Flynn GL. 1972. Solubility of organic hydrochlorides. J Pharm Sci 61:1896-1904.
28. Chowhan ZT. 1978. pH-solubility profiles of organic carboxylic acids and their salts. J Pharm Sci 67:1257-1260.
29. Serajuddin ATM, Pudipeddi M. 2002. Salt selection strategies. In: Stahl PH, Wermuth CG, editors. Handbook of pharmaceutical salts: Properties, selection, and use. Weinheim: Wiley-VCH. pp 135-160.
30. Carlson JA, Mann HJ, Canafax DM. 1983. Effect of pH on disintegration and dissolution of ketoconazole tablets. Am J Hosp Pharm 40:1334-1336.
31. Piscitelli SC, Goss TF, Wilton JH, D'Andrea DT, Goldstein H, Schentag JJ. 1991. Effects of ranitidine and sucralfate on ketoconazole bioavailability. J Antimicrob Agents Chemother 35: 1756:1771.
32. Ogata H, Aoyagi N, Kaniwa N, Ejima A, Sekine N, Kitamura M, Inoue Y. 1986. Gastric acidity dependent bioavailability of cinnarizine from two commercial capsules in healthy volunteers. Int J Pharm 29:113-120.
33. Ho NFH, Raub TJ, Burton PS, Barsuhn CL, Adson A, Audus KL, Borchardt RT. 2000. Quantitative approaches to delineate passive transport mechanisms in cell culture monolayers. In: Amidon GL, Lee PI, Topp EM, editors. Transport processes in pharmaceutical systems. New York: Marcel Dekker, pp 219-316.
34. Ellens H, Eddy EP, Lee C-P, Dougherty P, Lago A, Xiang J-N, Elliott JD, Cheng H-Y, Ohlstein E, Smith PL. 1997. In vitro permeability screening for identification of orally bioavailable endothelin receptor antagonists. Adv Drug Deliv Rev 23:99-109.
35. Berge SM, Bighley LD, Monkhouse DC. 1977. Pharmaceutical salts. J Pharm Sci 66:1-19.
36. Mooney KG, Mintun MA, Himmelstein KJ, Stella VJ. 1981. Dissolution kinetics of carboxylic acids. Part 1: effect of pH under unbuffered conditions. Part 2: effect of buffers. J Pharm Sci 70:13-22.
37. Serajuddin ATM, Jarowski C. 1985. Effect of diffusion layer pH and solubility on the dissolution rate of pharmaceutical acids and their sodium salts II: salicylic acid, theophylline, and benzoic acid. J Pharm Sci 74:148-154.
38. Ozturk SS, Palsson BO, Dressman JB. 1988. Dissolution of ionizable drugs in buffered and unbuffered solutions. Pharm Res 5:272-282.
39. Serajuddin ATM, Jarowski CI. 1985. Effect of diffusion layer pH and solubility on the dissolution rate of pharmaceutical bases and their hydrochloride salts. Part I. Phenazopyridine. J Pharm Sci 74:142-147.
40. Pudipeddi M, Serajuddin ATM, Grant DJW, Stahl PH. 2002. Solubility and dissolution of weak acids, bases, and salts. In: Stahl PH, Wermuth CG, editors. Handbook of pharmaceutical salts: Properties, selection, and use, Weinheim: Wiley-VCH. pp 19-39.
41. Serajuddin ATM, Jarowski CI. 1993. Influence of pH on release of phenytoin sodium from slow-release dosage forms. J Pharm Sci 82:306-310.
42. QDill WA, Kazenko A, Wolf LM, Glazko AJ. 1956. Studies on 5,5′-Diphenylhydantoin (Dilantin) in animals and man. J Pharmacol Exp Ther 118: 270-279.
43. Neuvonen PJ. 1979. Bioavailability of phenytoin: Clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinet 4:91-103.
44. Sawchuk RJ, Pepin SM, Leppik IE, Gummit RJ. 1982. Rapid and slow release phenytoin in epileptic patients at steady state: Comparative plasma levels and toxicity. J Pharmacokinet Biopharm 10:365-382.
45. Shah VP, Prasad VK, Alston T, Cabana BE, Gural RP, Meyer MC. 1983. Phenytoin I: in vitro-in vivo correlation of 100-mg phenytoin sodium capsules. J Pharm Sci 72:306-308.
46. Shah VP, Prasad VK, Freeman C, Kelly JP, Cabana BE. 1983. Phenytoin II: in vitro-in vivo bioequivalence standard for 100-mg phenytoin sodium capsules. J Pharm Sci 72:309-310.
47. Sawchuk RJ, Rector TS. 1979. Steady-state plasma concentration as a function of the absorption rate and dosing interval for drugs exhibiting concentration-dependent clearance: Consequences for phenytoin therapy. J Pharmacokinet Biopharm 7:543-555.
48. Arnold K, Gerber N, Levy G. 1970. Absorption and dissolution studies on sodium diphenylhydantoin capsules. Can J Pharm 5:89-92.
49. Serajuddin ATM, Sheen PC, Mufson D, Bernstein DF, Augustine MA. 1986. Preformulation study of a poorly water soluble drug, α-pentyl-3-(2- quinolinylmethoxy) benzenemethanol: Selection of the base for dosage form design. J Pharm Sci 75:492-496.
50. Walmsley LM, Taylor T, Wilkinson PA, Brodie RR, Chasseaud LF, Alun-Jones V, et al. 1986. Plasma concentrations and relative bioavailability of naftidrofuryl from different salt forms. Biopharm Drug Dispos 7:327-334.
51. Lin SL, Lachman L, Schwartz CJ, Huebner CF. 1972. Preformulation investigation I: Relation of salt forms and biological activity of an experimental antihypertensive. J Pharm Sci 61:1418-1422.
52. Li S, Doyle P, Metz S, Royce AE, Serajuddin ATM. 2005. Effect of chloride ion on dissolution of different salt forms of haloperidol, a model basic drug. J Pharm Sci (in press).
53. Aguiar AJ, Krc J, Kinkel AW, Samyn JC. 1967. Effect of polymorphism on the absorption of chloramphenicol from chlormphenicol palmitate. J Pharm Sci 56:847-853.
54. Pudipeddi M, Serajuddin ATM. 2005. Trends in solubility of polymorphs. J Pharm Sci 94:929-939.
55. Hancock BC, Parks M. 2000. What is the solubility advantage of amorphous pharmaceuticals? Pharm Res 17:397-404.
56. Fleisher D. 2000. Biological transport phenomena in the gastrointestinal tract: Cellular mechanisms. In: Amidon GL, Lee PI, Topp EM, editors. Transport processes in pharmaceutical systems. New York: Marcel Dekker. pp 147-184.
57. Winne D. 1977. Shift of pH-absorption curves. J Pharmacokinet Biopharm 5:53-94.
58. Shore PA, Brodie BB, Hogben CAM. 1957. The gastric secretion of drugs: A pH partition hypothesis. J Pharmacol Exp Ther 119:361-369.
59. Gibaldi M. 1991. Biopharmaceutics and clinical pharmacokinetics, 4th edn., Philadelphia: Lea and Febiger. pp 1-406.
60. Suzuki A, Higuchi WI, Ho NFH. 1970. Theoretical model studies of drug absorption and transport in the gastrointestinal tract. I. J Pharm Sci 59: 644-651.
61. Suzuki A, Higuchi WI, Ho NFH. 1970. Theoretical model studies of drug absorption and transport in the gastrointestinal tract. II. J Pharm Sci 59:651-659.
62. Swenson ES, Curatolo WJ. 1992. Means to enhance penetration: Intestinal permeability enhancement for proteins, peptides and other polar drugs: Mechanisms and potential toxicity. Adv Drug Deliv Rev 8:39-92.
63. Danielli JF, Davson HJ. 1935. A contribution to the theory of permeability of thin films. J Cell Comp Physiol 5:495-507.
64. Worthington CR, Blaurock AE. 1969. A structural analysis of nerve myelin. Biophys J 9:970-990.
65. Kramer SD. 1999. Absorption prediction from physicochemical parameters. Pharm Sci Technol Today 2:373-380.
66. Hansch C, Fujita T. 1964. ρ-σ-π Analysis. A method for the correlation of biological activity and chemical structure. J Am Chem Soc 86: 1616-1626.
67. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernas H, Hussain AS, Junginger HE, Stavchansky SA, Midha KK, Shah VP, Amidon GL. 2004. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 1:85-96.
68. Smith DA, Jones BC, Walker DK. 1996. Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Med Res Rev 16:243-266.
69. Young RC, Mitchell RC, Brown TH, Ganellin CR, Griffiths R, Jones M, Rana KK, Saunders D, Smith IR, Sore NE, Wilks TJ. 1988. Development of a new physiochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine anatagonists. J Med Chem 31:656-671.
70. Palm K, Luthman K, Ungell AL, Strandlund G, Artursson P. 1996. Correlation of drug absorption with molecular surface properties. J Pharm Sci 85:32-39.
71. Kelder J, Grootenhuis PDJ, Bayada DM, Delbressine LPC, Ploemen JP. 1999. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm Res 16:1514-1519.
72. Feher M, Sourial E, Schmidt JM. 2000. A simple model for prediction of blood-brain partitioning. Int J Pharm 201:239-247.
73. George A. 1999. The design and molecular modeling of CNS drugs. Curr Opin Drug Discovery Dev 2:286-292.
74. Clark DE, Pickett SD. 2000. Computational methods for the prediction of 'drug-likeness'. Drug Disc Today 5:49-58.
75. Ertl P, Rohde B, Selzer P. 2000. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 43:3714-3717.
76. Osiecka I, Porter PA, Borchardt RT, Fix JA, Gardner CR. 1985. In vitro drug absorption models. I. Brush border membrane vesicles, isolated mucosal cells and everted intestinal rings: Characterization and salicylate accumulation. Pharm Res 2:284-293.
77. Fix JA. 1996. Intestinal rings and isolated intestinalmucosal cells. In: Borchardt RT, Smith PL, Wilson G, editors. Models for assessing drug absorption and metabolism. New York: Plenum Press, pp 51-66.
78. Leppert PS, Fix JA. 1994. Use of everted intestinal rings for in vitro examination of oral absorption potential. J Pharm Sci 83:976-981.
79. Wilson TH, Wiseman G. 1954. The use of sacs of everted small intestine for the study of the transference of substances from the mucosal to the serosal surface. J Physiol 123:116-125.
80. Ussing HH, Zerahn K. 1951. Active transport of sodium as the source of electric current in the short-circulated isolated frog skin. Acta Physiol Scand 23:110-127.
81. Polentarutti BI, Peterson AL, Sjöberg AK, Anderberg EKI, Utter LM, Ungell A-LB. 1999. Evaluation of viability of excised rat intestinal segments in the Ussing chamber: Investigation of morphology, electrical parameters, and permeability constants. Pharm Res 16:446-454.
82. Hidalgo IJ. 1996. Cultured intestinal epithelial cell models. In: Borchardt RT, Smith PL, Wilson G, editors. Models for assessing drug absorption and metabolism, New York: Plenum Press, pp 35-50.
83. Artursson P, Karlsson J. 1991. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (CaCO-2) cells. Biochem Biophis Res Commun 175:880-885.
84. Volpe DA, Faustin PJ, Yu LX, Hussain AS. 2001. Towards standardization of an in vitro method of drug absorption. Pharmacopeial Forum 27(4).
85. Ho NFH, Park JY, Ni PF, Higuchi WI. 1983. Advancing quantitative and mechanistic approaches in interfacing gastrointestinal drug absorption studies in animals and humans. In: Crouthamel W, Sarapu AC, editors. Animal models for oral drug delivery in man; in situ and in vivo approaches. Washington DC: American Pharmaceutical Association, pp 27-106.
86. Lennernas H. 1998. Human intestinal permeability: An overview. J Pharm Sci 87:403-410.
87. Pithavala YK, Soria I, Zimmerman CL. 1997. Use of the deconvolution principle in the estimation of absorption and pre-systemic intestinal elimination of drugs. Drug Metab Dispos 25:1260-1265.
88. Hu M, Amidon GL. 1988. Passive and carrier-mediated intestinal absorption components of captopril. J Pharm Sci 77:1007-1011.
89. Wagner JG, Nelson E. 1964. Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug. J Pharm Sci 53:1392-1403.
90. Wagner JG. 1975. Application of the Loo-Riegelaman absorption method. J Pharmacokinet Biopharm 3:51-57.
91. Lennernas H, Ahrenstedt Ö, Hallgren R, Knutson L, Ryde M, Paalzow LK. 1992. Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharm Res 9:1243-1251.
92. Knutson L, Odlind B, Hallgren R. 1989. A new technique for segmental jejunal perfusion in man. Am J Gastroenterol 84:1278-1284.
93. Sandström R, Karlsson A, Knutson L, Lennernas H. 1998. Jejunal absorption and metabolism of R/S-verapamil in humans. Pharm Res 15:856-862.
94. Chiou WL, Ma C, Chung SM, Wu TC, Jeong HY. 2000. Similarity in the linear non-linear oral absorption of drugs between human and rat. Int J Clin Pharmacol Ther 38:532-539.
95. Chiou WL, Barve A. 1998. Linear correlation of the fraction of oral dose absorbed of 64 drugs between human and rats. Pharm Res 15:1792-1795.
96. Chiou WL, Buehler PW. 2002. Comparison of oral absorption and bioavailability of drugs between monkey and human. Pharm Res 19:868-874.
97. Chiou WL, Jeong HY, Chung SM, Wu TC. 2000. Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharm Res 17:135-140.
98. Lindahl A, Ungell AL, Lennernas H. 1997. Characterization of fluids from the stomach and proximal jejunum in men and women. Pharm Res 14:497-502.
99. Mahé S, Huneau JF, Marteau P, Thuillier F, Tome D. 1992. Gastroileal nitrogen and electrolyte movements after bovine milk ingestion in humans. Am J Clin Nutr 56:410-416.
100. Fordtran JS, Locklear TW. 1966. Ionic constituents and osmolarity of gastric and small intestinal fluids after eating. Am J Dig Dis 11:503-521.
101. Washington N, Washington C, Wilson CG. 2001. Physiological Pharmaceutics. New York: Taylor & Frances.
102. Malagelada JR, Longstreth GF, Summerskill WHJ, Go VLW. 1976. Measurement of gastric functions during digestion of ordinary solid meals in man. Gastroenterology 70:203-210.
103. Bakatselou V, Oppenheim RC, Dressman JB. 1991. Solubilization and wetting effects of bile salts on the dissolution of steroids. Pharm Res 8:1461-1469.
104. Cohen AF, Kroon R, Shoemaker R, Hoogkamer H, van Vliet A. 1991. Influence of gastric acidity on the bioavailability of digoxin. Ann Intern Med 115:540-545.
105. Charman WN, Porter CJH, Mithani S, Dressman JB. 1997. Physicochemical and physiological mechanisms for the effects of food on drug absorption: The effect of lipids and pH. J Pharm Sci 86:269-282.
106. Davis SS, Hardy JG, Fara JW. 1986. Transit of pharmaceutical dosage forms through the small intestine. Gut 27:886-892.
107. Bai JPF, Utis A, Crippen G, He HD, Fischer V, Tullman R, Yin H, Hsu M, Hwang KK, Polyakov V, Laoui A. 2004. The use of classification regression tree in predicting oral absorption in humans. J Chem Inf Comput Sci 44:2061-2069.
108. Agoram B, Woltosz WS, Bolger MB. 2001. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Delivery Rev 50:S41-S67.
109. Parrott N, Lave T. 2002. Prediction of intestinal absorption: Comparative assessment of GASTROPLUS and IDEA. Eur J Pharm Sci 17: 51-61.
110. Serajuddin ATM. 1999. Solid dispersion of poorly water soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 88:1058-1066.
111. Serajuddin ATM, Sheen PC, Mufson D, Bernstein DF, Augustine MA. 1988. Effect of vehicle amphiphilicity on the dissolution and bioavailability of a poorly water soluble drug from solid dispersions. J Pharm Sci 77:414-417.
112. Dannenfelser RM, He H, Joshi YM, Bateman S, Serajuddin ATM. 2004. Development of clinical dosage forms for a poorly water-soluble drug. I: Application of polyethylene glycol-polysorbate 80 solid dispersion carrier system. J Pharm Sci 93: 1165-1175.
113. Pouton CW. 1997. Formulation of self-emulsifying drug delivery systems. Adv Drug Deliv Rev 25:47-58.
114. Charman SA, Charman WN, Rogger MC, Wilson TD, Dutko FJ, Pouton CW. 1992. Self-emulsifying systems: Formulation and biological evaluation of an investigative lipophilic compound. Pharm Res 9:87-94.
115. Serajuddin ATM, Sheen P, Mufson D, Bernstein DF, Augustine MA. 1988. Physicochemical basis of increased bioavailability of a poorly water-soluble drug following oral administration as organic solutions. J Pharm Sci 77:325-329.
116. US Department of Health and Human Services. 1997. Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlation. Center for Drug Evaluation and Research (CDER). Rockville, MD.
117. Dressman JB. 2000. Dissolution testing of immediate-release products and its application to forecasting in vivo performance. In: Dressman JB, Lennernas H, editors. Oral drug absorption: Prediction and assessment, New York: Marcel Dekker Inc., pp 155-181.
118. Macheras P, Koupparis M, Antimisiaris S. 1989. In vitro model for exploring CR theophylline-milk fat interactions. J Pharm Sci 54:123-130.
119. Shah VP, Konecny JJ, Everett RL, McCullough B, Noorizadeh AC, Skelly JP. 1989. In vitro dissolution profile of water-insoluble drug dosage forms in the presence of surfactants. Pharm Res 6:612-618.